{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-011536","form_type":"8-K","ticker":"PURE","cik":"0001006028","company_name":"PURE BIOSCIENCE, INC.","filed_at":"2024-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.068500+00:00","generated_at":"2026-06-04T06:54:18.383743+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Pure Bioscience raises $500K via convertible notes from director; up to $3M total","bullets":["Initial $500,000 private placement of convertible promissory notes to accredited investors, including board member Tom Y. Lee.","Interest at 7.81% compounded annually; maturity 3 years from issuance.","Conversion price tied to 30-day VWAP, with floor $0.13 and cap $0.21 per share.","Subsequent closings allowed up to $3M aggregate principal through July 31, 2024.","Notes convertible at holder's or company's option; automatic conversion after one year if majority holders elect."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-011536","json":"https://secwatch.observer/filing/0001493152-24-011536.json","markdown":"https://secwatch.observer/filing/0001493152-24-011536.md","text":"https://secwatch.observer/filing/0001493152-24-011536.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006028/000149315224011536/0001493152-24-011536-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006028/000149315224011536/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T06:54:18.383743+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9684ff7d7de8c8d6270254e5dabf71539156b005","claim":"PURE BIOSCIENCE, INC. incurred convertible notes of $500,000 with certain accredited investors at 7.81%, compounded annually maturing the third-year anniversary of the date of issuance.","evidence_excerpt":"On March 22, 2024, Pure Bioscience, Inc. (the “Company”) entered into a Note Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (“Lenders”) pursuant to which the Company issued the Lenders convertible promissory notes (the “Notes”, collectively with the Note Purchase Agreement, the “Notes Documents”) with an aggregate principal balance of $500,000 (the “Private Placement”).","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1006028/000149315224011536/0001493152-24-011536-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$500,000"},{"label":"Counterparty","value":"certain accredited investors"},{"label":"Rate","value":"7.81%, compounded annually"},{"label":"Maturity","value":"the third-year anniversary of the date of issuance"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"3860c58437e63758b7999c9d7bf192e58f39b297","claim":"PURE BIOSCIENCE, INC. entered into Note Purchase Agreement with certain accredited investors valued at $500,000 (effective 2024-03-22).","evidence_excerpt":"On March 22, 2024, Pure Bioscience, Inc. (the “Company”) entered into a Note Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (“Lenders”) pursuant to which the Company issued the Lenders convertible promissory notes (the “Notes”, collectively with the Note Purchase Agreement, the “Notes Documents”) with an aggregate principal balance of $500,000 (the “Private Placement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1006028/000149315224011536/0001493152-24-011536-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"notes offering"},{"label":"Counterparty","value":"certain accredited investors"},{"label":"Value","value":"$500,000"},{"label":"Effective","value":"2024-03-22"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}